QIAGEN N.V. (QIA.DE) Stock Price & Overview
FRA:QIA • NL0015002SN0
Current stock price
The current stock price of QIA.DE is 34.465 EUR. Today QIA.DE is up by 0.64%. In the past month the price decreased by -16.18%. In the past year, price decreased by -11.03%.
QIA.DE Key Statistics
- Market Cap
- 7.102B
- P/E
- 16.18
- Fwd P/E
- 15.36
- EPS (TTM)
- 2.13
- Dividend Yield
- 0.65%
QIA.DE Stock Performance
QIA.DE Stock Chart
QIA.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to QIA.DE. When comparing the yearly performance of all stocks, QIA.DE is a bad performer in the overall market: 85.33% of all stocks are doing better.
QIA.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to QIA.DE. QIA.DE scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
QIA.DE Earnings
On February 5, 2026 QIA.DE reported an EPS of 0.62 and a revenue of 540.42M. The company missed EPS expectations (-3.03% surprise) and missed revenue expectations (-0.31% surprise).
QIA.DE Forecast & Estimates
24 analysts have analysed QIA.DE and the average price target is 47.13 EUR. This implies a price increase of 36.74% is expected in the next year compared to the current price of 34.465.
For the next year, analysts expect an EPS growth of 5.2% and a revenue growth 6.7% for QIA.DE
QIA.DE Groups
Sector & Classification
QIA.DE Financial Highlights
Over the last trailing twelve months QIA.DE reported a non-GAAP Earnings per Share(EPS) of 2.13. The EPS increased by 10.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.33% | ||
| ROA | 6.75% | ||
| ROE | 11.25% | ||
| Debt/Equity | 0.44 |
QIA.DE Ownership
QIA.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| DIM | SARTORIUS STEDIM BIOTECH | 31.52 | 15.904B | ||
| SRT3 | SARTORIUS AG-VORZUG | 36.32 | 15.725B | ||
| 56S1 | SARTORIUS STEDIM BIOTECH | 30.57 | 15.656B | ||
| SRT | SARTORIUS AG | 28.95 | 12.415B | ||
| 1SXP | SCHOTT PHARMA AG& CO KGAA | 12.19 | 1.967B | ||
| 1EVT | EVOTEC SE | N/A | 1.501B | ||
| EVT | EVOTEC SE | N/A | 1.475B | ||
| GXI | GERRESHEIMER AG | 8 | 651.079M | ||
| FF | FINE FOODS & PHARMACEUTICALS | 11.69 | 180.892M | ||
| MLC | MALIN CORP PLC | N/A |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About QIA.DE
Company Profile
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Company Info
IPO: 1996-09-01
QIAGEN N.V.
Hulsterweg 82
Venlo LIMBURG NL
Employees: 5654
Phone: 31773556600
QIAGEN N.V. / QIA.DE FAQ
What does QIA do?
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Can you provide the latest stock price for QIAGEN N.V.?
The current stock price of QIA.DE is 34.465 EUR. The price increased by 0.64% in the last trading session.
Does QIAGEN N.V. pay dividends?
QIAGEN N.V. (QIA.DE) has a dividend yield of 0.65%. The yearly dividend amount is currently 0.
What is the ChartMill technical and fundamental rating of QIA stock?
QIA.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is QIAGEN N.V. (QIA.DE) stock traded?
QIA.DE stock is listed on the Frankfurt Stock Exchange exchange.
What is QIAGEN N.V. worth?
QIAGEN N.V. (QIA.DE) has a market capitalization of 7.10B EUR. This makes QIA.DE a Mid Cap stock.